🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05120830
Active, not recruiting Phase 1/2

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 · tracked via the Priya Life Science UK tracker
Sponsor
Intellia Therapeutics
Phase
Phase 1/2
Started
2021-12-10
Last updated
2026-03-24

Condition(s) studied

Hereditary Angioedema

Investigational drug(s) / intervention(s)

Biological NTLA-2002Normal Saline IV Administration

Biological NTLA-2002: CRISPR/Cas9 gene editing system delivered by LNP for IV administration

Normal Saline IV Administration: The administration of IV normal saline

Study summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age \>18 years 2. Diagnosis of HAE Types I or II 3. Ability to provide evidence of HAE attacks to meet the screening requirement 4. Subjects must have access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks. 5. Adequate chemistry and hematology measures at screening 6. Subjects must agree not to participate in another interventional study for the duration of this trial. 7. Subjects must be capable of providing signed informed consent Exclusion Criteria: 1. Concurrent diagnosis of any other type of recurrent angioedema 2. Subjects who have known negative reaction or hypersensitivity to any lipid nanoparticles (LNP) component. 3. Any condition that, in the Investigator's opinion, could adversely affect the safety of the subject. 4. Unwilling to comply with study procedures.

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
Clinical Trial Site Campbelltown Australia
Clinical Trial Site Grenoble France
Clinical Trial Site Lille France
Clinical Trial Site Paris France
Clinical Trial Site Berlin Germany
Clinical Trial Site Frankfurt Germany
Clinical Trial Site Amsterdam Netherlands
Clinical Trial Site Auckland New Zealand
Clinical Trial Site Cambridge United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05120830 on ClinicalTrials.gov ↗ ← All trials in the UK